Company intelligence / Profile preview
Shaanxi Dongke Pharmaceutical
Xianyang, Shaanxi, Chinashaanxidk.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Shaanxi Dongke Pharmaceutical has received IND approval for a drug candidate targeting psoriasis of the scalp and has completed clinical bioequivalence studies on montelukast sodium granules in healthy Chinese subjects. The company also develops and markets oral care products based on traditional Chinese medicine with anti-inflammatory properties.
- Therapeutic areas
- OtherPulmonologyDermatologyImmunology
- Modalities
- Small moleculeGranule formulationTransdermal preparation
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Shaanxi Dongke Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shaanxi Dongke Pharmaceutical.